In human-TNBC-xenograft-bearing mice given human immune cells, weekly treatment with SNS-032 followed by the anti-PD-L1 antibody avelumab demonstrated a reduction in tumor growth, compared with SNS-032 inhibition only or with anti-PD-L1 antibody alone, in the absence of overt toxic effects. This evidence concerns the gene CD274 and neoplasm.